scispace - formally typeset
H

Hua Zhong

Researcher at Rutgers University

Publications -  54
Citations -  6339

Hua Zhong is an academic researcher from Rutgers University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 17 publications receiving 6047 citations. Previous affiliations of Hua Zhong include Johns Hopkins University & Emory University.

Papers
More filters
Journal Article

Overexpression of Hypoxia-inducible Factor 1α in Common Human Cancers and Their Metastases

TL;DR: The first clinical data indicating that HIF-1alpha may play an important role in human cancer progression are provided, indicating adaptations to a hypoxic microenvironment that are correlated with tumor invasion, metastasis, and lethality.
Journal Article

Modulation of Hypoxia-inducible Factor 1α Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics

TL;DR: It is demonstrated that in human prostate cancer cells, basal-, growth factor- and mitogen-induced expression of hypoxia-inducible factor 1 (HIF-1) alpha, the regulated subunit of the transcription factor Hif-1, is blocked by LY294002 and rapamycin, inhibitors of PI3K and FRAP, respectively.
Journal ArticleDOI

Expression of hypoxia‐inducible factor 1α in brain tumors

TL;DR: The authors tested the hypothesis that HIF‐1 expression correlates with progression and angiogenesis in brain tumors and found no evidence that it correlates with disease progression.
Journal ArticleDOI

Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia.

TL;DR: The results suggest that 28S rRNA is a reliable internal control for comparative analyses of transcription under hypoxia; GAPDH appears particularly unfavorable for this purpose either in Hypoxia or other experimental conditions that upregulate HIF-1alpha.
Journal Article

Geldanamycin Induces Degradation of Hypoxia-inducible Factor 1α Protein via the Proteosome Pathway in Prostate Cancer Cells

TL;DR: It is shown that treatment of prostate cancer PC-3 and LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, induced degradation of HIF-1alpha protein in a dose- and time-dependent manner under both normoxia and hypoxia.